Open Orphan #ORPH – Successful completion of PrEP Biopharm Toxicology study for respiratory ‘viral mimic’ December 23, 2020 – Posted in: Open Orphan (ORPH)

Phase IIb study to validate efficacy of PrEP-001 against circulating respiratory viruses such as COVID-19, flu and the common cold Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, announces that drug development company PrEP Biopharm Limited (“PrEP Biopharm”), which is 62.6% owned by Open Orphan, has successfully completed a 12-week toxicology study for its novel…

Continue reading